Increased Sale Proceeds from FibroGen China
The sale of FibroGen China to AstraZeneca now expected to bring approximately $185 million, a $25 million increase from initial guidance due to greater than expected net cash in China at closing.
Extension of Cash Runway
The increased proceeds from the FibroGen China sale are expected to extend the company's cash runway into the second half of 2027.
Promising Clinical Developments
Phase 1 monotherapy study of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) showed a median radiographic progression-free survival of 8.7 months, with an overall response rate of 20%.
Regulatory Milestones Achieved
FDA cleared the IND for FG-3180, a companion PET imaging agent, marking an important achievement for FibroGen.
Cost Reductions
Total operating costs and expenses for the first quarter of 2025 were $17.7 million, a decrease of 76% year-over-year.